Equity Profile

GH

Guardant Health, Inc.

Health CareHealth Care Services$16.7B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Guardant Health, Inc. is a healthcare company focused on precision oncology, providing blood tests for cancer detection and monitoring....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will show how well the company is managing its costs relative to its revenue.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales, crucial for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GH Q2-2026 Earnings Preview

Context

Company Snapshot

Guardant Health, Inc. is a healthcare company focused on precision oncology, providing blood tests for cancer detection and monitoring. With a market cap of $17 billion, it plays a significant role in the growing field of cancer diagnostics, leveraging advanced technology to improve patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+38.36%

Avg Stock Reaction

+1.55%

Last Quarter Recap

In Q1-2026, Guardant Health reported an EPS of -$0.45, beating expectations by 36.89%. The stock saw a slight increase of 0.01% the following day, indicating cautious optimism among investors.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has consistently beaten EPS estimates in recent quarters. However, the lack of revenue guidance leaves uncertainty about future growth.

Bull Case

If Guardant continues its trend of beating EPS estimates, it could signal strong operational efficiency and investor confidence, potentially driving the stock higher.

Bear Case

On the other hand, if the company fails to provide clear revenue growth indicators or guidance, it may lead to investor disappointment and a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's history of beating EPS estimates, this number will be crucial in determining market sentiment and stock performance.

What guidance will management provide regarding revenue growth?

Clear revenue guidance is essential for understanding the company's growth trajectory and will heavily influence investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Guardant to continue its EPS beat trend, given its recent operational improvements.

Supporting Evidence

The company has consistently beaten EPS estimates in the past eight quarters, indicating strong management performance.

Options pricing suggests a significant move, indicating that investors are anticipating volatility, which could favor a positive outcome.

Key Risk

If the EPS comes in below -$0.50, it could undermine the positive sentiment built from previous quarters.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to maintain its EPS beat trend while providing clear revenue growth guidance.

Bull Confirmed If

An EPS of -$0.30 or better would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS worse than -$0.50 would confirm the bear case, suggesting potential issues in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±28.22%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±28.2% while GH has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.6%

Calls (119K)P/C Ratio: 0.19Puts (15K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$9,840.28

116 sh

1 insider

Net

$9,840.28

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Guardant beats expectations and raises guidance, history suggests a potential average one-day move of +1.55%, confirming strong operational health.

In-Line / Cautious

If results are in line but management is cautious, the stock may react moderately, reflecting uncertainty in future growth.

Miss

If the company misses EPS expectations, history suggests a potential average one-day move of -4.64%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on new product launches or advancements in technology.
2Updates on partnerships or collaborations that could enhance market reach.
3Insights into customer acquisition strategies and market expansion plans.
4Management's perspective on competitive pressures in the oncology space.
5Any changes in regulatory landscape that could impact operations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Guardant Health, Inc. is a healthcare company focused on precision oncology, providing blood tests for cancer detection and monitoring....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will show how well the company is managing its costs relative to its revenue.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales, crucial for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+38.36%

Avg Stock Reaction

+1.55%

Last Quarter Recap

In Q1-2026, Guardant Health reported an EPS of -$0.45, beating expectations by 36.89%. The stock saw a slight increase of 0.01% the following day, indicating cautious optimism among investors.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has consistently beaten EPS estimates in recent quarters. However, the lack of revenue guidance leaves uncertainty about future growth.

Bull Case

If Guardant continues its trend of beating EPS estimates, it could signal strong operational efficiency and investor confidence, potentially driving the stock higher.

Bear Case

On the other hand, if the company fails to provide clear revenue growth indicators or guidance, it may lead to investor disappointment and a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's history of beating EPS estimates, this number will be crucial in determining market sentiment and stock performance.

What guidance will management provide regarding revenue growth?

Clear revenue guidance is essential for understanding the company's growth trajectory and will heavily influence investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Guardant to continue its EPS beat trend, given its recent operational improvements.

Supporting Evidence

The company has consistently beaten EPS estimates in the past eight quarters, indicating strong management performance.

Options pricing suggests a significant move, indicating that investors are anticipating volatility, which could favor a positive outcome.

Key Risk

If the EPS comes in below -$0.50, it could undermine the positive sentiment built from previous quarters.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to maintain its EPS beat trend while providing clear revenue growth guidance.

Bull Confirmed If

An EPS of -$0.30 or better would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS worse than -$0.50 would confirm the bear case, suggesting potential issues in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±28.22%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±28.2% while GH has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.6%

Calls (119K)P/C Ratio: 0.19Puts (15K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$9,840.28

116 sh

1 insider

Net

$9,840.28

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Guardant beats expectations and raises guidance, history suggests a potential average one-day move of +1.55%, confirming strong operational health.

In-Line / Cautious

If results are in line but management is cautious, the stock may react moderately, reflecting uncertainty in future growth.

Miss

If the company misses EPS expectations, history suggests a potential average one-day move of -4.64%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on new product launches or advancements in technology.
2Updates on partnerships or collaborations that could enhance market reach.
3Insights into customer acquisition strategies and market expansion plans.
4Management's perspective on competitive pressures in the oncology space.
5Any changes in regulatory landscape that could impact operations.